The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
B Ungar, Y Chowers, M Yavzori, O Picard, E Fudim… - Gut, 2014 - gut.bmj.com
Objective To characterise the temporal evolution of antibodies to infliximab (ATI). Design
Prospective observational study of infliximab-treated patients with inflammatory bowel disease …
Prospective observational study of infliximab-treated patients with inflammatory bowel disease …
Optimizing anti-TNF-α therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases
B Ungar, I Levy, Y Yavne, M Yavzori, O Picard… - Clinical …, 2016 - Elsevier
Background & Aims It is not clear what serum levels of anti–tumor necrosis factor are associated
with reduced intestinal inflammation in patients with inflammatory bowel disease (IBD). …
with reduced intestinal inflammation in patients with inflammatory bowel disease (IBD). …
Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab
…, Y Bujanover, Y Rosenbach, B Ungar… - Clinical …, 2015 - Elsevier
Background & Aims There is controversy about whether levels of anti–tumor necrosis factor (TNF)
and antidrug antibodies (ADAs) are accurate determinants of loss of response to …
and antidrug antibodies (ADAs) are accurate determinants of loss of response to …
Prospective observational evaluation of time-dependency of adalimumab immunogenicity and drug concentrations: the POETIC study
B Ungar, T Engel, D Yablecovitch, A Lahat… - Official journal of the …, 2018 - journals.lww.com
OBJECTIVES: Adalimumab is usually self-injected at home, making prospective serial-sampling
studies challenging and scarce. This has led to a gap in knowledge about evolution of …
studies challenging and scarce. This has led to a gap in knowledge about evolution of …
Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima
…, M Yavzori, I Benhar, E Fudim, O Picard, B Ungar… - Gut, 2016 - gut.bmj.com
Objective The cross-immunogenicity of the recently approved infliximab-biosimilar Remsima
(CT-P13) with the originator drug Remicade is still unknown. Design Sera of patients with …
(CT-P13) with the originator drug Remicade is still unknown. Design Sera of patients with …
Vedolizumab in IBD–lessons from real-world experience; a systematic review and pooled analysis
T Engel, B Ungar, DE Yung, S Ben-Horin… - Journal of Crohn's …, 2018 - academic.oup.com
Background Vedolizumab [VDZ] is an anti-integrin monoclonal antibody effective in ulcerative
colitis [UC] and Crohn’s disease [CD]. Several real-world experience [RWE] studies with …
colitis [UC] and Crohn’s disease [CD]. Several real-world experience [RWE] studies with …
Association of induction infliximab levels with clinical response in perianal Crohn's disease
Y Davidov, B Ungar, H Bar-Yoseph… - Journal of Crohn's …, 2017 - academic.oup.com
Background: The association of infliximab [IFX] trough levels with clinical and endoscopic
outcomes in inflammatory bowel disease is well established. However, there is scarce data …
outcomes in inflammatory bowel disease is well established. However, there is scarce data …
Association of vedolizumab level, anti-drug antibodies, and α4β7 occupancy with response in patients with inflammatory bowel diseases
B Ungar, U Kopylov, M Yavzori, E Fudim… - Clinical …, 2018 - Elsevier
Background & Aims There are few data available on the real-life pharmacokinetic and
pharmacodynamics features of vedolizumab, a monoclonal antibody against integrin α4β7. We …
pharmacodynamics features of vedolizumab, a monoclonal antibody against integrin α4β7. We …
Efficacy and safety of vedolizumab for induction of remission in inflammatory bowel disease—the Israeli real-world experience
…, M Waterman, S Daher, B Ungar… - Inflammatory bowel …, 2017 - academic.oup.com
Background Vedolizumab (VDZ) is an anti-integrin monoclonal antibody effective in ulcerative
colitis (UC) and Crohn's disease (CD). The aim of this study was to examine the “real world…
colitis (UC) and Crohn's disease (CD). The aim of this study was to examine the “real world…
Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence
…, C Ma, B Pariente, P WIls, R Eliakim, B Ungar… - Digestive and Liver …, 2019 - Elsevier
Background Ustekinumab [UST] is effective in Crohn’s disease (CD) in the UNITI studies.
Several real-world experience (RWE) studies with UST have been published to date. Our aim …
Several real-world experience (RWE) studies with UST have been published to date. Our aim …
In response to a complaint we received under the US Digital Millennium Copyright Act, we have removed 1 result(s) from this page. If you wish, you may read the DMCA complaint that caused the removal(s) at LumenDatabase.org.